Camp4 Therapeutics Corp
CAMP
Company Profile
Business description
Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. The company focuses on genetic diseases of the central nervous system and liver. Its pipeline products include CMP-CPS-001 and CMP-SYNGAP. The company operates as a single operating segment, R&D, which engages in the development of a new class of RNA-based therapeutics to treat a broad range of genetic diseases.
Contact
One Kendall Square
Building 1400 West, 3rd Floor
CambridgeMA02139
USAT: +1 617 651-8867
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
48
Stocks News & Analysis
stocks
Corning’s AI fiber boom is real, but its stock price may be getting out of hand
Corning’s optical fiber business is thriving, and the Meta deal derisks its supply buildout, but success isn’t guaranteed.
stocks
Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?
From AI integration to capital expenditure increases, here’s what we expect in Alphabet’s earnings report.
stocks
ASX energy share remains cheap despite strong outlook
Santos reports a solid quarter on the back of higher commodity prices - yet the shares look undervalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,935.00 | 14.40 | -0.16% |
| CAC 40 | 8,104.09 | 37.83 | -0.46% |
| DAX 40 | 24,018.26 | 65.27 | -0.27% |
| Dow JONES (US) | 49,185.92 | 18.13 | 0.04% |
| FTSE 100 | 10,332.79 | 11.70 | 0.11% |
| HKSE | 25,679.78 | 245.87 | -0.95% |
| NASDAQ | 24,569.70 | 317.40 | -1.28% |
| Nikkei 225 | 59,917.46 | 619.90 | -1.02% |
| NZX 50 Index | 12,764.40 | 110.54 | -0.86% |
| S&P 500 | 7,122.88 | 51.03 | -0.71% |
| S&P/ASX 200 | 8,710.70 | 10.50 | -0.12% |
| SSE Composite Index | 4,078.64 | 7.71 | -0.19% |